Selected category: myasthenia gravis

By Constanze Drechsel

Myasthenia gravis is an autoimmune disease affecting 14-20/100,000 people in the U.S.¹ and 1-9/100,000 people in Europe.² The sad truth is that most of those afflicted go undiagnosed. Myasthenia gravis causes severe muscle weakness and significantly decreases quality of life. Diagnosis can be difficult, but state-of-the-art disease biomarkers and targeted assays are available to increase the likelihood that a patient with myasthenia gravis will be diagnosed early and can be treated appropriately. How can these biomarkers and use of the correct assays also help clinicians monitor therapeutic efficacy and support better treatment outcomes for their patients?

By Anne Hartenhauer

More than 90% of patients with signs and symptoms of myasthenia gravis can be readily detected and treated with a range of effective therapies. The key to early diagnosis and treatment that can lead to remission is the selection of sensitive, specific, and proven assays to detect and quantify the autoantibodies that cause myasthenia gravis. Fortunately, there are high-quality assays on the market that can save you valuable time in diagnostic procedures*, eliminate the need to develop in-house solutions, and ensure accurate and early disease detection.

By Anne Hartenhauer

“Myasthenia gravis is eminently treatable,” say researchers at UCL’s Institute of Neurology¹. Yet clinicians still find it challenging to detect and manage. In a new webinar entitled “Autoantibodies in Myasthenia Gravis,” Dr. Jan Damoiseaux, a Laboratory Specialist in Medical Immunology at Maastricht UMC+ in the Netherlands, explores the underlying mechanisms of the disease and explains how a two-assay strategy can improve the accuracy of determination of autoantibodies and help monitor therapeutic efficacy to improve patient outcomes.

By Anne Hartenhauer

Myasthenia gravis is an autoimmune disease with an estimated prevalence of 14-20/100,000 population in the U.S.¹ and 1-9 /100,000 population in Europe.² Many affected individuals go undiagnosed. Myasthenia gravis can cause severe muscle weakness and greatly impact quality of life. Diagnosis can be difficult, but state-of-the-art disease biomarkers and targeted assays are available to increase the likelihood that a patient with myasthenia gravis is diagnosed early and can be treated appropriately. How can these biomarkers and use of the correct assays also help clinicians monitor therapeutic efficacy and support better treatment outcomes for their patients?